Immunome (NASDAQ:IMNM) Issues Earnings Results, Misses Expectations By $0.16 EPS

Immunome (NASDAQ:IMNM - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16), Zacks reports. The firm had revenue of $2.74 million for the quarter, compared to analysts' expectations of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%.

Immunome Stock Down 5.5 %

Shares of Immunome stock traded down $0.48 during trading hours on Friday, hitting $8.18. The company's stock had a trading volume of 4,323,434 shares, compared to its average volume of 826,503. Immunome has a 1-year low of $8.17 and a 1-year high of $26.70. The business has a fifty day moving average of $9.76 and a 200 day moving average of $11.55. The company has a market capitalization of $652.58 million, a PE ratio of -1.01 and a beta of 1.93.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Wedbush reaffirmed an "outperform" rating and set a $33.00 price target on shares of Immunome in a research report on Thursday. Lifesci Capital assumed coverage on shares of Immunome in a research report on Tuesday, March 11th. They set an "outperform" rating and a $20.00 price target for the company. Guggenheim dropped their price target on shares of Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday. Finally, Stephens reaffirmed an "overweight" rating and set a $30.00 price target on shares of Immunome in a research report on Thursday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome presently has a consensus rating of "Buy" and a consensus price target of $25.50.

Remove Ads

Insider Transactions at Immunome

In other Immunome news, CEO Clay B. Siegall acquired 150,000 shares of the company's stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the transaction, the chief executive officer now directly owns 669,636 shares of the company's stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 8.60% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.